A Phase 1, Open-Label, Study of the Effect of Cimetidine, a Known Inhibitor of Active Renal Secretion, on the Single-Dose Pharmacokinetics of Intravenously-Administered Methylnaltrexone in Healthy Adults

Trial Profile

A Phase 1, Open-Label, Study of the Effect of Cimetidine, a Known Inhibitor of Active Renal Secretion, on the Single-Dose Pharmacokinetics of Intravenously-Administered Methylnaltrexone in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Cimetidine; Methylnaltrexone bromide
  • Indications Constipation; Gastro-oesophageal reflux; Peptic ulcer
  • Focus Pharmacokinetics
  • Sponsors Progenics Pharmaceuticals
  • Most Recent Events

    • 21 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top